Real-World Evidence of Reductions in Health Resource Utilization (HRU) and Improved Efficacy Outcomes Associated with Reslizumab Treatment in Adults with Severe Eosinophilic Asthma (SEA) in the United States

In clinical trials, reslizumab improved lung function and decreased clinical asthma exacerbation (CAE) frequency in SEA patients; however, real-world data are limited. We collected data on patients treated in U.S. clinical practice to assess the real-world effectiveness of reslizumab. A retrospective chart review collected patient-level data on adults with SEA receiving reslizumab for ≥7 months. Patient outcomes in the 6 months pre- and...